About a year ago Merck KGaA made the controversial decision to revive its late-stage program for the cancer vaccine Stimuvax, trying to start off fresh by renaming it tecemotide and pointing it toward a subpopulation of non-small cell lung cancer patients which appeared to respond in its very big failed Phase III. Today, the program is–once again–officially terminated.

…read more

Source: Merck KGaA scraps a controversial PhIII comeback attempt for cancer vaccine


0 No comments